

Federal Circuit Rules for Axinn Client in Tamiflu Patent Appeal

A decorative graphic on the right side of the page features a light blue and white grid pattern that curves and flows downwards, resembling a stylized ribbon or a modern architectural element.

NEWS | 1 MIN READ

April 25, 2014

HARTFORD, Conn.--(BUSINESS WIRE)--A ruling by the U.S. Court of Appeals for the Federal Circuit has given **Axinn** client **Natco Pharma Ltd.** a second chance at invalidating **Gilead Sciences Inc.'s** patent on the popular flu drug Tamiflu. The decision could pave the way to Natco's planned issuance of a generic version of the drug in the United States. Natco was represented by Axinn attorney [Thomas Hedemann](#).

The April 22 Federal Circuit ruling vacated a December 2012 district court ruling that Gilead did not unlawfully extend a patent covering Tamiflu and remanded the issue of the patent's validity back to the district court for reconsideration.

This is the first time the Federal Circuit has addressed whether a commonly-owned patent that issues after — but expires before — another patent can be rendered invalid for double-patenting. By ruling that it can, the court reaffirmed the double patenting doctrine, which prohibits inventors from unreasonably extending patent protection past the statutory limit.

The ruling also establishes a bright-line rule for patent practitioners and continues to provide inventors like Natco Pharma with the ability to use terminal disclaimers to overcome obviousness-type double patenting rejections.

In March, the U.S. Food and Drug Administration (USFDA) granted Natco tentative approval to sell its generic version of Tamiflu in the U.S. market. The approval, however, is contingent upon

Natco successfully resolving its patent dispute with Gilead Sciences.

Related People



Thomas K. Hedemann

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum
EVENT
- SABA North America Corporate Counsel Retreat 2025
SPONSORSHIP ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
CLIENT ALERTS ANTITRUST

- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
AWARDS & RECOGNITIONS ANTITRUST
- Merger Remedies Back in Vogue Under Trump
MEDIA MENTIONS ANTITRUST
- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation
AXINN VIEWPOINTS INTELLECTUAL PROPERTY
- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness
AXINN VIEWPOINTS INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved